[Federal Register Volume 66, Number 202 (Thursday, October 18, 2001)]
[Notices]
[Page 52929]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-26217]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Analogs of Thalidomide 
as Potential Angiogenesis Inhibitors''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. Patent 
Application S/N 60/271,941, entitled ``Analogs of Thalidomide as 
Potential Angiogenesis Inhibitors,'' filed on February 27, 2001, to 
Celgene Corporation of Warren, NJ.
    The prospective exclusive license territory will be worldwide and 
the field of use may be therapeutics for the treatment of oncology and 
inflammatory diseases.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before December 17, 
2001 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Matthew B. Kiser, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. Telephone: 
(301) 496-7056, X224; Facsimile (301) 402-0220; E-mail 
[email protected].

SUPPLEMENTARY INFORMATION: U.S. Patent Application S/N 60/271,941 
discloses several novel thalidomide analogs that mimic the effects of 
the ``active'' thalidomide. The compounds show enhanced potency in the 
inhibition of angiogenesis without the undesirable effects of 
administration of thalidomide.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 4, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-26217 Filed 10-17-01; 8:45 am]
BILLING CODE 4140-01-M